GlucoTrack (NASDAQ:GCTK) Trading Down 0.3% – What’s Next?

GlucoTrack, Inc. (NASDAQ:GCTK)’s stock price traded down 0.3% on Thursday . The company traded as low as $6.31 and last traded at $6.43. 27,702 shares traded hands during trading, a decline of 72% from the average session volume of 100,413 shares. The stock had previously closed at $6.45.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GlucoTrack in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

GlucoTrack Trading Down 0.3%

The stock has a market capitalization of $5.79 million, a PE ratio of -0.01 and a beta of 0.22. The firm has a 50 day moving average price of $6.32 and a 200 day moving average price of $7.12. The company has a quick ratio of 3.27, a current ratio of 3.27 and a debt-to-equity ratio of 0.03.

GlucoTrack (NASDAQ:GCTK) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($9.62) EPS for the quarter.

Institutional Investors Weigh In On GlucoTrack

A hedge fund recently raised its stake in GlucoTrack stock. Bank of America Corp DE grew its position in GlucoTrack, Inc. (NASDAQ:GCTK) by 102,125.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,089 shares of the company’s stock after purchasing an additional 4,085 shares during the period. Bank of America Corp DE owned about 0.85% of GlucoTrack worth $25,000 at the end of the most recent reporting period. 10.92% of the stock is owned by hedge funds and other institutional investors.

About GlucoTrack

GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain.